Diabetic ketoacidosis induced by alpha interferon and ribavirin treatment in a patient with hepatitis C [5] (multiple letters)

American Journal of Gastroenterology

Volumn 96, Issue 2, 2001, Pages 604-605

  Bhatti, Ahsan ^a   McGarrity, Thomas J ^a   Gabbay, Robert ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; RIBAVIRIN;

ADULT; ARTERIAL GAS; ARTERIAL PH; AUTOIMMUNITY; BLOOD GLUCOSE MONITORING; CASE REPORT; CHRONICITY; CLINICAL FEATURE; DEHYDRATION; DIABETIC KETOACIDOSIS; DRUG EFFECT; DRUG RESPONSE; DYSPNEA; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; HEPATITIS C; HISTOLOGY; HUMAN; LETTER; LIVER BIOPSY; NAUSEA; PATHOGENESIS; PRIORITY JOURNAL; SYMPTOM; TREATMENT OUTCOME; VIRUS LOAD; VOMITING;

EID: 0035120531     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(00)02364-9     Document Type: Letter

References (11)

1. Pathogenesis, natural history, treatment and prevention of hepatitis C
2. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994
3. Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
4. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
5. Increased risk for autoimmune thyroid disease in hepatitis C vs hepatitis B before, during and after discontinuing interferon therapy
6. Autoimmunity and thyroid function in patients with chronic hepatitis treated with recombinant interferon alpha-2a
7. Extrahepatic syndromes associated with hepatitis C infection
8. Celiac disease during interferon treatment
9. Effect of interferon on glucose tolerance and insulin sensitivity
10. Diabetes mellitus and interferon α therapy
11. Development of type 1 diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis